Preclinical results support entinostat's role in targeting the tumor microenvironment

(The Wistar Institute) Syndax Pharmaceuticals, Inc. ('Syndax,' the 'Company' or 'we') (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (progr...